NCT03355157: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting.

NCT03355157
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 4
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: 
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled/untreated central nervous system lesions
https://ClinicalTrials.gov/show/NCT03355157

Comments are closed.

Up ↑